Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer

Figure 2

Correlation of plasma s-Met and patients’ gender, age, and tumor subtype as well as clinical and histopathological characteristics. s-Met in plasma was measured, respectively, in 146 Chinese lung cancer patients and 40 disease-free volunteers. Individuals were grouped into subgroups according to gender, and s-Met among subgroups was compared (a); correlation of individuals (including patients and disease-free volunteers) age and s-Met (b); s-Met was compared between small cell lung cancer (SCLC) patients and non-small cell lung cancer (NSCLC) patients (c); s-Met was compared between patients with/without metastasis (d); s-Met among patients in various clinical stages was compared; means significant difference against stage I subgroups, (e); s-Met among tumors with various differentiation was compared; means significant difference against well differentiated subgroups, (f).

(a)

(b)

(c)

(d)

(e)

(f)